CeriBell Quietly Holds Ground as Options Turn Bullish

CBLL heads into Q3 earnings season with a stock that has ground steadily higher, up 2.5% on the week and 4.8% over the past month to $24.86, while its options market has undergone a sharp shift from defensive to outright bullish positioning.

The most striking development in the data this week is the options setup. The put/call ratio has collapsed to just 0.07, roughly one-fifth of its 20-day average of 0.48. That is 1.2 standard deviations below the mean, close to the lowest PCR reading of the past year (the 52-week floor is 0.03). Earlier this month the ratio was above 0.85, a level consistent with genuine downside hedging. That reversal, from heavy put demand to overwhelmingly call-dominated flow, is the clearest near-term signal in the snapshot. The borrow market adds little drama: availability is effectively unlimited, with 15.3 million shares available and the lending pool barely touched. Short interest runs at roughly 2.9% of the free float, a modest level that has drifted lower over the past month, down about 15% from late May. There is no short-side squeeze pressure and no indication that the bear trade is building.

The Street is uniformly positive, though coverage is thin. BTIG reiterated its Buy rating and a $30 target on 11 September, after raising that target from $28 following the August earnings print. Canaccord Genuity also lifted its target to $26 post-results. The mean analyst target of $28 sits roughly 13% above the current price, which is directionally consistent with the bull case: an AI-powered EEG platform gaining commercial traction in neurocritical care, with FDA clearance now extended to pediatric and neonatal patients. The bear case centres on cash burn, ongoing IP litigation, and uncertainty around the path to breakeven. Valuation multiples reflect the pre-profitability reality: price-to-book has expanded sharply over the past 30 days and the EV/EBITDA multiple is deeply negative, so the stock is priced purely on growth expectations rather than current earnings power.

The August earnings print supplied the most concrete data point for bulls. The stock jumped 18.7% the day after reporting, then extended to a 25.4% gain over the following five trading days. A prior event in the same quarter produced a similar outcome, a 13.3% one-day move followed by a 29.7% five-day gain. Both episodes show the stock has rewarded positive news decisively. The next scheduled print is 10 November, 41 days away.

Insider activity warrants a note, though its signal is limited. The CEO, CFO, and senior finance officer all sold shares in September, with the CEO's transaction the largest at just over $520,000. Every one of these sales was executed under a pre-arranged 10b5-1 plan, which means the transactions were scheduled in advance and carry less interpretive weight than discretionary selling. The 90-day net insider position is negative at roughly $5.7 million, but the preponderance of plan-driven sales makes it difficult to read as a conviction call on valuation. On the institutional side, FMR (Fidelity) remains the largest holder at close to 15% of shares, and raised its stake again as of July. BlackRock crossed the 5% threshold and filed a fresh 13G in late July. TPG, an early backer, has been reducing, trimming from 11.1% to 7.8% as of August. No Schedule 13D activist is on the register, so there is no activist angle in play. Stakes are as last disclosed around the 5% threshold, and holders dropping below that level may not file again.

Among correlated peers, the week's performance was mixed. KMTS gained 9.1% and SGHT added 8.8%, both outpacing CBLL's 2.5% move. BBNX dropped nearly 15%, the sharpest decline in the group. CBLL's steady, undramatic week looks like relative stability in a peer set with wider price swings in both directions.

With Q3 results six weeks away and the options market leaning heavily toward calls, the 10 November print will determine whether the post-August momentum can hold.